Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
5
83%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated233%
completed350%
not_yet_recruiting117%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_1

A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

NCT07454291
terminatedphase_1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795
completedphase_2

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT04968574
completedphase_1

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

NCT05817240
terminatedphase_1

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

NCT02530437
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07454291Phase 1

A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

Not Yet Recruiting
NCT02784795Phase 1

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Terminated
NCT04968574Phase 2

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Completed
NCT05817240Phase 1

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Completed
NCT02530437Phase 1

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

Terminated
NCT01226485Phase 1

A Study in Advanced Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6